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Abstract
Purpose The diagnosis of osteomyelitis is a challenge for
diagnostic imaging. Nuclear medicine procedures including
white blood cell imaging have been successfully used for the
identification of bone infections. This multinational, phase III
clinical study in 22 European centres was undertaken to
compare anti-granulocyte imaging using the murine IgG
antibody besilesomab (Scintimun®) with
99mTc-labelled
white blood cells in patients with peripheral osteomyelitis.
Methods A total of 119 patients with suspected osteomy-
elitis of the peripheral skeleton received
99mTc-besilesomab
and
99mTc-hexamethylpropyleneamine oxime (HMPAO)-
labelled white blood cells (WBCs) in random order
2–4 days apart. Planar images were acquired at 4 and
24 h after injection. All scintigraphic images were
interpreted in an off-site blinded read by three experienced
physicians specialized in nuclear medicine, followed by a
fourth blinded reader for adjudication. In addition, clinical
follow-up information was collected and a final diagnosis
was provided by the investigators and an independent truth
panel. Safety data including levels of human anti-mouse
antibodies (HAMA) and vital signs were recorded.
W. S. Richter
Pharmtrace klinische Entwicklung GmbH,
Alt-Moabit 59-61,
10555 Berlin, Germany
W. S. Richter:H. Amthauer
Clinics for Radiology and Nuclear Medicine,
University Clinics Magdeburg,
Leipziger Strasse 44,
39120 Magdeburg, Germany
V. Ivancevic
Nuclear Medicine Celle,
Siemensplatz 4,
29223 Celle, Germany
J. Meller
Department of Nuclear Medicine,
University Medicine (UMG) Göttingen,
Robert-Koch-Str. 40,
37075 Göttingen, Germany
O. Lang
Department of Nuclear Medicine, Charles University,
3rd Medical Faculty, UH Kralovske Vinohrady,
Šrobarova 50,
100 34 Prague, Czech Republic
D. Le Guludec
CHU Bichat-Claude Bernard, Service de Médecine Nucléaire,
46 rue Henri Huchard,
75877 Paris Cedex 18, France
I. Szilvazi
Department of Nuclear Medicine,
Országos Gyógyintézeti Központ,
Szabolcs u. 33,
1135 Budapest, Hungary
F. Chossat: A. Dahmane
IBA/CIS bio international,
BP 32,
91192 Gif sur Yvette Cedex, France
C. Schwenke
SCOSSIS,
Zeltinger Strasse 58 G,
13465 Berlin, Germany
A. Signore (*)
Nuclear Medicine Unit, “Sapienza” University of Rome,
2nd Faculty of Medicine,
Ospedale S. Andrea, Via di Grottarossa 1035,
00189 Rome, Italy
e-mail: alberto.signore@uniroma1.it
Eur J Nucl Med Mol Imaging (2011) 38:899–910
DOI 10.1007/s00259-011-1731-2Results The agreement in diagnosis across all three readers
between Scintimun® and
99mTc-HMPAO-labelled WBCs
was 0.83 (lower limit of the 95% confidence interval 0.8).
Using the final diagnosis of the local investigator as a
reference, Scintimun® had higher sensitivity than
99mTc-
HMPAO-labelled WBCs (74.8 vs 59.0%) at slightly lower
specificity (71.8 vs 79.5%, respectively). All parameters
related to patient safety (laboratory data, vital signs) did not
provide evidence of an elevated risk associated with the use
of Scintimun® except for two cases of transient hypoten-
sion. HAMA were detected in 16 of 116 patients after scan
(13.8%).
Conclusion Scintimun® imaging is accurate, efficacious
and safe in the diagnosis of peripheral bone infections
and provides comparable information to
99mTc-HMPAO-
labelled WBCs.
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Introduction
The diagnosis of osteomyelitis is a challenge for physicians
and diagnostic imaging because of a substantial heteroge-
neity in its possible clinical presentations. Diagnosis is
usually based on a combination of clinical, laboratory and
imaging findings. Whereas clinical and laboratory data
provide general evidence of an inflammatory process,
diagnostic imaging is typically used to detect and document
osteomyelitic changes in specific bones or joints.
There is not one single optimal imaging method for
patients with suspected osteomyelitis. Instead, the most
appropriate imaging modality has to be selected on the
basis of the individual strengths and limitations of each
imaging approach and depends also on patient-specific
factors such as disease history, comorbidity and the location
of the suspected disease process. The imaging modalities
most widely used in suspected osteomyelitis include X-ray,
conventional bone scintigraphy, CT and MRI. While
conventional X-ray may show characteristic changes in
later osteomyelitis, early diagnosis is frequently missed,
particularly when the inflammatory process is limited to the
medullary space of the bone as, e.g. in early haematogenous
osteomyelitis [1]. In addition, X-ray diagnosis is considered
to be neither sensitive nor specific in the case of suspected
prosthetic joint infection [2].
CTmayprovideusefulhigh-definitionimages,particularly
for peripheral osteomyelitis, whereas MRI has emerged as a
promising method for its superior soft tissue contrast and the
high anatomical resolution. Limitations of CT and MRI are
related to the presence of artefacts in patients after joint
replacement and to difficulties regarding the differentiation
between osteomyelitis and other diseases with similar
symptoms, e.g. the differentiation between diabetic foot and
Charcot neuropathic osteoarthropathy [3–5].
Conventional bone scintigraphy almost always identifies
osteomyelitic lesions but is also positive in a wide variety
of non-osteomyelitic conditions and, therefore, suffers from
a limited specificity. Imaging of white blood cells (WBCs)
with scintigraphic methods is used as an adjunct tool to
distinguish between infection and sterile inflammation and
other disorders in areas that are abnormal on bone scans.
The combination of conventional bone scanning and WBC
scintigraphy has proven to be a clinically useful approach
in patients with suspected osteomyelitis [6].
Different scintigraphic methods are available for WBC
imaging. In vitro labelling of WBCs with
111In or
99mTc is
regarded as the gold standard; however, this approach is
cumbersome as it requires in vitro separation of WBCs,
their radioactive labelling and re-injection of the labelled
WBCs into the patient [7–9]. In vitro labelling of WBCs is
also associated with infection risks for personnel and
patients and a high radiation burden to technicians in
charge of the labelling [6]. The recent availability of a
closed system device for WBC labelling
1 has greatly
reduced these problems, but in vivo labelling of WBCs
still represents an attractive alternative to direct in vitro
labelling, particularly because it reduces preparation time.
The first approach regarding in vivo labelling was the
murine IgG1k antibody BW 250/183 (
99mTc-besilesomab,
Scintimun®) which recognizes the nonspecific cross-
reacting antigen 95 (NCA-95; also referred to as CD66b
and CEACAM8) in the cytoplasm and on the cell
membranes of granulocytes and granulocyte precursor cells.
Radiolabelled besilesomab has been used since 1992 in
Switzerland, Hungary, the Czech Republic and Sweden on
the basis of local marketing approvals and in Germany (on
the basis of individual prescription). Since 1992, an
estimated 100,000 patients have been diagnosed with
Scintimun® in these countries. In January 2010, Scintimun®
was granted a marketing authorization for all European
countries by the European Medicines Agency (EMEA) for
determining the location of infection in peripheral bone in
adults with suspected osteomyelitis.
This article reports the results of the recent phase III
clinical trial comparing Scintimun® with
99mTc-hexame-
thylpropyleneamine oxime (HMPAO)-labelled WBCs in
peripheral osteomyelitis. The trial was conducted with the
primary aim of evaluating diagnostic concordance between
the two techniques and as secondary aims to evaluate the
sensitivity, specificity and image quality of Scintimun®
and
99mTc-HMPAO-labelled WBCs in acute and chronic
peripheral osteomyelitis.
1 http://www.leukokit.com/home.htm
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Study design
This study was a randomized, open-label, intraindividual
comparison, multicentre phase III clinical trial with 22
study centres in Europe (see Annex for a listing of all study
centres). Patients with suspected or documented osteomy-
elitis were assigned to receive two scintigraphic examina-
tions in random order: one scintigraphy with
99mTc-
besilesomab (Scintimun®) and one scintigraphy with
99mTc-HMPAO-labelled WBCs. The minimum acceptable
interval between the two examinations was 2 days, and the
maximum acceptable interval was 4 days.
Study procedures included planar scintigraphic imaging
at 4 and 24 h after injection of each radiopharmaceutical,
the documentation of vital signs and adverse events, the
determination of serum levels of human anti-mouse anti-
bodies (HAMA), and the determination of laboratory values
[complete blood count including differential blood count,
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), gamma-glutamyltranspeptidase (GT), alkaline phos-
phatase, total bilirubin, conjugated bilirubin, creatinine,
non-fasting glucose, chloride, potassium, sodium, total
protein, albumin, alkaline reserve, urea, calcium, C-
reactive protein (CRP) including the coagulation profile
(prothrombin time and activated partial thromboplastin
time)]. The primary efficacy variable was the agreement
rate of Scintimun® and
99mTc-HMPAO-labelled WBCs
with regard to the diagnosis of infection or sterile
inflammation, based on the evaluation of three blinded
and independent readers in a central image analysis.
Secondary efficacy variables included image quality and
sensitivity/specificity/accuracy of the reader’s diagnoses
using the final assessment of the local investigator as the
reference. The final assessment of the investigator was
obtained at 1 month after scintigraphic imaging and took
into account all available clinical information including
data on follow-up and the results of all imaging procedures.
In addition, an independent truth panel reviewed the
medical history and the clinical findings of the patients and
gave a final assessment on the presence of infection or
sterile inflammation and the affected body regions. The
truth panel was provided with all relevant clinical informa-
tion, the results of all diagnostic imaging procedures related
to infection (except information about the results of
imaging with Scintimun® and
99mTc-HMPAO-labelled
WBCs) and information about the further follow-up of the
patients up to 12 months after scintigraphy (where
available). The truth panel was composed of three physi-
cians (one nuclear medicine specialist, one radiologist and
one orthopaedist). All decisions of the truth panel were
derived by consensus. Based on the assessment of the truth
panel, the sensitivity, specificity and accuracy of Scinti-
mun® and
99mTc-HMPAO-labelled WBCs were calculated
as an additional secondary analysis.
The protocol was reviewed and approved by the local and/
or central independent Ethics Committees and the responsible
regulatory authorities of each study centre. The study was
conducted in accordance with all local legal and regulatory
requirements,theethicalprinciplesthathavetheirorigininthe
Declaration of Helsinki, and the International Conference on
Harmonisation (ICH) guideline E6 (Good Clinical Practice).
Patientswereonlyincluded inthe study after havingprovided
informed consent in writing.
Patients
Male or female patients aged 18 or older could be recruited,
provided they presented with suspected or documented
osteomyelitis (acute, subacute, chronic) of the peripheral
skeleton. Patients with loosening of joint prosthesis and
patients with diabetic foot were accepted for the study. All
patients had to present with at least one of the following
signs or symptoms: localized pain, non-healing skin
ulceration, fever above 37.8°C for at least 3 days, leukocyte
count in excess of the upper normal limit, erythrocyte
sedimentation rate in excess of the upper normal limit,
radiographic findings suggestive of osteomyelitis, or posi-
tive blood or wound cultures.
Patients were not allowed to enter the study if they were
pregnant or breast-feeding, had a history of allergy to mouse
proteins, had a history of idiosyncratic reactions to any drug,
had a positive HAMA test prior to first study radiopharma-
ceutical administration, suffered from hereditary fructose
intolerance, had suffered from a severe disease or had
undergone surgery (except for orthopaedic reasons) within
4 weeks prior to first study radiopharmaceutical administra-
tion, or had a leukocyte count below 4×10
9/l. Further
exclusion criteria included the use of non-steroidal anti-
inflammatory drugs and corticosteroids within 3 days prior
to first study radiopharmaceutical administration as well as
the intake of cancer chemotherapy, immunosuppressive
drugs, and immunomodulators within 4 weeks prior to study
entry. Patients were not allowed to participate in another
study within 1 month prior to screening. No other nuclear
medicine diagnostic procedure was accepted within 2 days
prior to first study radiopharmaceutical administration.
Scintimun® and
99mTc-HMPAO-labelled WBCs
Scintimun® (IBA/CIS bio international, Saclay, France) was
supplied as a kit containing two types of vials (vial 1 and vial
2). Reconstitution and quality control of the final solution
were done according to the procedure described in the
Summary of Product Characteristics (SmPC). The radio-
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24 mCi) per injection (patient) as proposed by the
respective guideline of the German Society of Nuclear
Medicine. Radiochemical purity (RCP) of Scintimun®
was checked prior to injection in all but two patients of
the per protocol (PP) population. RCP was above 95% in
116 patients and RCP was below 95% in 1 patient
(91.9%). The mean RCP was 97.7%, standard deviation
1.7%, and the median 97.8%.
Ex vivo labelling of WBCs with
99mTc was performed
using Ceretec™ (GE Healthcare, Buc, France). Prepara-
tion, labelling and quality control of
99mTc-HMPAO-
labelled WBCs had to follow the procedures described in
the SmPC of Ceretec™. Individual trial sites were allowed
to deviate from these procedures if validated procedures
for WBC labelling were in place at that site for routine
diagnostic studies. The radioactivity dose of
99mTc-
HMPAO-labelled WBCs was 250–400 MBq (7–11 mCi)
per injection (patient). Labelling efficiency (LE) was
assessed in 117 patients of the PP population (2 patients
with missing values); the mean value of LE was 61.1%
(standard deviation 15.5%, median 61.5%). According to
the recent guidelines of the European Association of
Nuclear Medicine (EANM) for labelling of leukocytes
with
99mTc-HMPAO, LE is expected to be between 40 and
80% [7].
Scintigraphy
Planar scintigraphic images including anterior and posterior
views of the affected body regions (ipsilateral and contra-
lateral) were acquired at 4 and 24 h after each radiotracer
administration. Whole-body acquisitions were accepted.
The investigator was free to acquire additional views (e.g.
lateral views) or to perform single photon emission
computed tomography (SPECT). SPECT/CT was never
performed. During all acquisitions with both tracers,
imaging had to follow the same procedures and the same
views were to be obtained. All planar images available
were processed for the central blinded read.
A large field of view gamma camera equipped with low-
energy high-resolution collimator had to be used. If count
rates were low on 24-h images, centres were free to use a
low-energy all-purpose (LEAP) collimator for late imaging.
For both tracers and all time points, images were to be
acquired with either a minimum of 800 kcounts per view or
an acquisition time of 15 min. The pulse height analyser of
the gamma camera had to be centred at 140 keV with an
energy window of 15–20%. Patients had to be studied with
the same camera/computer system during Scintimun® and
99mTc-HMPAO-labelled WBC studies. All images were
subjected to a quality assurance procedure at the blinded
read core lab to assure consistent quality standards.
Laboratory assessments and safety parameters
Laboratory assessments were obtained before and 24 h
after injection of each tracer and included serum
chemistry, haematology, inflammation parameters and
coagulation profile. A final laboratory assessment was
obtained after 1 month. The presence of HAMA in serum
was assessed at screening and at days 30 and 90 after
Scintimun® scintigraphy using the commercial HAMA-
ELISA kit from medac (Hamburg, Germany). Vital signs
(blood pressure and heart rate) were assessed before and
a f t e re a c hi n j e c t i o n( a t5m i n ,4ha n d2 4h ) ;a d v e r s e
events were recorded from the first tracer injection until
1 month after injection.
Central (blinded) image analysis
The blinded image analysis was performed in three
sessions. During the first session, all patients were shown
once to each of three blinded readers. Readers saw either
the Scintimun® images or the
99mTc-HMPAO-labelled
WBC images (4- and 24-h images). The readers had to
identify areas of infection/inflammation by drawing appro-
priate regions of interest (ROIs). Furthermore, readers had
to assess body segments contralateral to each identified
infectious or sterile inflammatory lesion. These contralater-
al body sides were expected to be normal (unaffected by
infection or inflammation) and were required for the
calculation of the agreement rate in normal regions and
for the calculation of specificity. Further assessments
included the level of diagnostic confidence, image quality
and the final diagnosis.
The second session was conducted in the same way as
the first session; however, the second available image set
had to be assessed by the reader (e.g. if Scintimun® images
were presented during the first session,
99mTc-HMPAO-
labelled WBC images were presented during the second
session). The time interval between reading sessions 1 and
2 was at least 3 weeks to avoid information carryover.
During the third session, a fourth blinded reader
evaluated all image pairs (Scintimun® and
99mTc-
HMPAO-labelled WBCs) of each patient with the ROIs
drawn by the three blinded readers. The fourth reader had to
decide if, for each reader, the sites identified by ROIs on
Scintimun® and
99mTc-HMPAO-labelled WBC images
represented the identical area of infection or inflammation.
In the same way, this fourth reader had to assess the
contralateral body side for identity of assessments.
All blinded readers were certified in nuclear medicine
and had experience in scintigraphy of infection or inflam-
mation. The readers were independent and did not
participate in the clinical part of the study. During their
assessments, all readers were blinded with regard to all
902 Eur J Nucl Med Mol Imaging (2011) 38:899–910clinical information; the first three readers were also
blinded with regard to the tracer.
Statistics
Analyses were performed in the all subjects examined
(ASE) population for safety and in the PP population for
efficacy. The ASE population consisted of all randomized
patients who received at least one of the two study
treatments. The PP population consisted of all patients
who completed all study procedures including imaging with
99mTc-HMPAO-labelled WBCs and Scintimun® without
major protocol violations. The agreement rate was analysed
using a modified adjusted χ
2 test to cover clustered data
and multiple measurements per cluster [8]. The limit of
clinical relevance was set to 0.7, and agreement between
both methods was concluded when the 95% confidence
interval (CI) for the agreement rate was positioned above
0.7. For further analyses of efficacy, summary statistics,
frequency counts and CIs were computed, as appropriate.
The primary efficacy variable was the agreement rate
between Scintimun® and
99mTc-HMPAO-labelled WBCs
calculated as an average across the results of the three
blinded readers. For each reader, the agreement rate was
calculated after adjudication by the fourth reader taking into
consideration all sites identified as affected by infection or
sterile inflammation together with the respective segments
on the contralateral body side (which were expected to be
unaffected by infection or inflammation):(number of agreed
affected sites + number of agreed not affected sites)/(total
number of all affected and not affected sites)
Continuous data were compared between treatment
groups by t test, and categorical data by χ
2 tests. The
image quality was compared between the treatment groups
by multivariate regression analysis based on generalized
estimation equations taking into account the multiple
measurements of each image by the three readers. Inde-
pendence was used as working correlation matrix with a
cumulative logit function as link function. Statistical
significance was concluded with two-sided p values below
0.05. All calculations were performed with SAS 9.2 (SAS
Institute, Cary, NC, USA).
Results
A total of 141 patients were screened for the study. Of
these, 121 received both study radiopharmaceuticals, 2
patients received Scintimun® only, 7 patients dropped out
before any study radiopharmaceutical administration and 11
patients were screening failures. The ASE population for
safety consisted of 123 patients who received at least one of
the two study radiopharmaceuticals: 61 in the treatment
sequence “Scintimun® first” a n d6 2p a t i e n t si nt h e
treatment sequence “
99mTc-HMPAO-labelled WBCs first”.
The PP population for efficacy consisted of 120 patients
who received both study radiopharmaceuticals and com-
pleted all required study procedures including scintigraphic
imaging without major protocol violations: 59 patients in
the treatment sequence Scintimun® first and 61 patients in
the sequence
99mTc-HMPAO-labelled WBCs first. One
patient from the PP population was excluded from the
analyses of agreement rates because he was not assessed by
one of the three blinded readers. All results reported here
refer to 119 patients of the PP population who were
assessed by all blinded readers. Details about these 119
patients are summarized in Table 1.
The primary efficacy variable of the study was the
agreement rate between Scintimun® and
99mTc-HMPAO-
labelled WBCs after adjudication by the fourth reader. The
agreement rate across all readers was 0.83 with a lower
limit of the 95% CI at 0.8. The lower limit of the 95% CI
was clearly above the predefined level of 0.7 (p<0.0001)
and, therefore, the primary objective of study AG-PH3 was
met and a clinically relevant and statistically significant
agreement between Scintimun® and
99mTc-HMPAO-labelled
WBCs demonstrated. Results for the agreement rate by
reader are summarized in Table 2.
In a secondary analysis, the sensitivity and specificity of
both tracers were calculated using the final diagnosis of the
local investigator at the 1-month follow-up as the reference.
For this assessment, the local investigator had to make use of
all available clinical information (including Scintimun® and
99mTc-HMPAO-labelled WBC imaging). The investigator
assessment was compared with the results of the blinded
read in a patient-based manner, i.e. patients were regarded as
positive if at least one lesion was identified in the blinded
read (irrespective of the location of the lesion) or negative if
no lesion was identified in the blinded read. At the 1-month
follow-up, the local investigator rated 73 patients as
suffering from infection or sterile inflammation, while 39
were rated as normal. Seven patients were excluded from
this analysis because the final assessment of the local
investigator was missing. Using the final diagnosis of the
local investigator as the reference, Scintimun® had higher
sensitivity than
99mTc-HMPAO-labelled WBCs (74.8 vs
59.0%) and slightly lower specificity (71.8 vs 79.5%) (see
Table 3 for detailed results).
An additional patient-based analysis was performed
using a truth panel assessment as the reference. The truth
panel was provided with all relevant clinical data including
12 months of follow-up information (where available).
Information about the results of imaging with Scintimun®
and
99mTc-HMPAO-labelled WBCs was not provided to the
truth panel. The truth panel was able to establish a final
diagnosis in 74 patients: 41 patients were assessed as
Eur J Nucl Med Mol Imaging (2011) 38:899–910 903positive (suffering from infection or sterile inflammation)
and 33 were assessed as negative. Also from this analysis,
Scintimun® showed higher sensitivity than
99mTc-HMPAO-
labelled WBCs (75.6 vs 62.6%) and slightly lower
specificity (68.7 vs 75.8%, respectively).
Microbiological cultures were obtained in 17patients of the
PP population. Of these 17 patients, 7 had infection as proven
by a positive microbiological culture. With Scintimun®, all
three blinded readers correctly identified six of these patients
andmissed one(sensitivityacrossreaders 85.7%). With
99mTc-
HMPAO-labelled WBCs, two readers correctly identified
four positive patients and one reader correctly identified three
positive patients (sensitivity across readers 61.9%).
This phase III study was primarily designed to assess the
agreement between Scintimun® and
99mTc-HMPAO-labelled
WBCs regarding infection or inflammation without distinc-
tion between those two conditions. In clinical practice,
however, a differentiation between infection and sterile
inflammation is required because of the different ensuing
therapeutic consequences. To address this aspect, an
analysis was performed in the subgroup of patients in
whom the local investigator was able to make a
distinction between sterile inflammation and infection
on the basis of the 1-month follow-up. This assessment
of the local investigator at 1 month was compared to his
assessment obtained directly after each of the two
imaging procedures. In total, 34 patients were classified
by the local investigator as having an infection and 31 as
having a sterile inflammation. The image interpretation
criteria for infection were based on the increase of
activity in suspected areas or the increase of size
showing uptake with time, by comparing images at
4a n d2 4h( F i g s .1 and 2). In this subgroup, Scintimun®
had a sensitivity of 47% for correct identification of
infection, a specificity of 77% and an overall accuracy of
62%. The respective values for
99mTc-HMPAO-labelled
WBCs were 44% for sensitivity, 87% for specificity and
65% for overall accuracy. The difference between the two
radiopharmaceuticals was statistically not significant.
Acute vs chronic infection or inflammation
In 95 patients clinical symptoms started earlier than 6 weeks
before inclusion into the study. These patients were
classified as suffering from “chronic” disease [9]. In the
remaining 24 patients, the onset of clinical symptoms was
within 6 weeks before inclusion and these patients were
classified as suffering from “acute” disease. The agree-
ment rate between Scintimun® and
99mTc-HMPAO-
labelled WBCs after adjudication by the fourth reader
w a s0 . 7 9i nt h ec h r o n i cg r o u pa n d0 . 8 0i nt h ea c u t eg r o u p .
Taking the final diagnosis of the investigator as the
reference, Scintimun® exhibited a significantly higher
sensitivity than
99mTc-HMPAO-labelled WBCs in patients
with chronic disease. Further details of this analysis are
summarized in Table 4.
Scintimun® first WBCs first p value
a
Total number 59 60
Men 38 (64%) 35 (58%) 0.4963
Age
b 62 ± 13 61 ± 16 0.7140
Height
b 170 ± 10 169 ± 13 0.5120
Weight
b 84 ± 15 81 ± 18 0.3477
Clinical symptoms
Localized pain 10 (17%) 7 (12%) 0.4103
Non-healing skin ulceration 39 (66%) 47 (78%) 0.1362
Fever >37.8°C for at least 3 days 57 (97%) 57 (95%) 0.6616
Other clinical symptoms 44 (75%) 50 (83%) 0.2410
Biological signs of infection
c 28 (47%) 21 (35%) 0.1674
Imaging findings suggestive of infection
d 28 (47%) 33 (55%) 0.4105
Loosening of joint prosthesis 29 (49%) 33 (55%) 0.5232
Diabetic foot 13 (22%) 12 (20%) 0.7854
Table 1 Details of 119 patients
of the PP population
ap values of comparisons of
groups, t test for continuous data,
χ
2 test for categorical data
bArithmetic mean ± 1 standard
deviation
cLeukocyte count or erythrocyte
sedimentation rate above upper
limit of normal, or positive blood
or wound cultures
dImaging includes X-ray, CT, MRI,
bone scan and other procedures (but
does not include Scintimun® and
labelled WBCs)
Agreement rate Standard error Lower limit of the 95% CI
Reader 1 0.81 0.02 0.76
Reader 2 0.84 0.02 0.79
Reader 3 0.85 0.02 0.80
Across all 3 readers 0.83 0.01 0.80
Table 2 Agreement rate by
reader between Scintimun® and
99mTc-HMPAO-labelled WBCs
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During the blinded read, each reader also had to assess the
quality of images on a 4-point scale as poor, moderate,
good or excellent. The results are summarized in Table 5.
The cumulated frequency of good and excellent images was
267 (75%) for Scintimun® and 199 (56%) for
99mTc-
HMPAO-labelled WBCs. The difference in image quality
between both tracers was significant (χ
2 test based on a
multinomial regression, p<0.0001), although different
amounts of radioactivity were injected for the two types
of scans.
Fig. 1 A 40-year-old patient
presenting with pain in the area
of the left tibia. His history
included a motorcycle accident
almost 4 years earlier with se-
vere trauma of the left body
side. WBC imaging was per-
formed to rule out osteomyelitis.
The Scintimun® study showed
increased uptake in the upper
inner part of the left tibia con-
sistent with material infection.
The labelled WBC study
showed low uptake at 4 h but
rather normal images at 22 h. At
surgery 4 months after imaging
no evidence of infection was
found. The truth panel rated this
patient as abnormal (suffering
from infection or inflammation)
Scintimun®
99mTc-HMPAO-labelled WBCs
Sensitivity 95% CI Sensitivity 95% CI
Reader 1 0.770 0.674; 0.867 0.703 0.598; 0.808
Reader 2 0.757 0.658; 0.855 0.514 0.399; 0.628
Reader 3 0.716 0.613; 0.820 0.554 0.440; 0.668
Across readers 0.748 0.666; 0.829 0.590 0.497; 0.683
Specificity 95% CI Specificity 95% CI
Reader 1 0.641 0.575; 0.861 0.667 0.517; 0.817
Reader 2 0.795 0.667; 0.923 0.897 0.801; 0.994
Reader 3 0.718 0.575; 0.861 0.821 0.699; 0.943
Across readers 0.718 0.594; 0.842 0.795 0.703; 0.887
Table 3 Sensitivity and speci-
ficity of Scintimun® and
99mTc-
HMPAO-labelled WBCs using
the final diagnosis of the local
investigator at the 1-month
follow-up as the reference
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patient admitted for non-healing
defect with fistula of the second
toe of the right foot with redness
and swelling but without fever.
Based on the initial clinical
examination, osteomyelitis in
the right foot was suspected and
the patient was admitted to the
hospital. Laboratory examina-
tions revealed an elevated CRP;
blood leukocytes were normal.
Multiresistant Staphylococcus
aureus was cultivated from the
bone biopsy; control cultivation
4 months after antibiotic therapy
was negative. Scintimun® and
99mTc-HMPAO-labelled WBC
studies show a lesion of focal
increasing uptake of radioactivity
with time at the second toe. The
uptake at the level of the left
metatarsus decreasing with time
was detected only by Scintimun®
and can be interpreted as sterile
inflammation (Charcot osteo-
arthropathy)
Table 4 Sensitivity and specificity of Scintimun® and
99mTc-HMPAO-labelled WBCs separately for patients with chronic and acute infection or
inflammation
No. of patients
a Scintimun®
99mTc-HMPAO-labelled WBCs
Sensitivity
Chronic 60 0.733 (0.638; 0.829) 0.544* (0.440; 0.649)
Acute 13 0.846
c 0.821
c
Specificity
Chronic 28 0.726 (0.587; 0.865) 0.774** (0.652; 0.895)
Acute 11 0.697
b 0.848
b
95% CI shown in parentheses
*p<0.05 vs.Scintimun®; **p=n.s. vs Scintimun®
aTotal number of patients with final diagnosis of the investigator is 112 (73 patients positive for infection/inflammation and 39 patients negative for
infection /inflammation; 7 patients without final diagnosis by the investigator)
bCI and significance level not calculated because of low cluster size
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Amongst the 123 patients of the ASE population who
received at least one of the two study radiopharmaceuticals,
24 patients (19%) reported a total of 31 adverse events. Of
these 31 adverse events, 14 (45%) were related to infectious
or inflammatory disease and 2 (6%) were assessed as
possibly or probably related to Scintimun® and concerned 2
cases of mild and transient hypotension. Only one patient
experienced a serious adverse event during study participa-
tion. This patient suffered from necrosis at the level of the
metatarsus and was hospitalized for transmetatarsal ampu-
tation after completion of scintigraphic imaging. His health
condition deteriorated during hospitalization, a gastroscopy
revealed haemorrhage of a duodenal ulcer and he finally
died from cardiopulmonary failure. This serious adverse
event was assessed by the investigator as unrelated to study
radiopharmaceuticals.
Laboratory assessments, vital signs and HAMA
Assessment of laboratory parameters was comparable between
the two study groups (Scintimun® first and
99mTc-HMPAO-
labelled WBCs first). The majority of abnormal laboratory
values was already abnormal before the first injection of
study radiopharmaceutical and was related to the inflamma-
tory process. Mean values did not change from baseline after
administration of Scintimun® or
99mTc-HMPAO-labelled
WBCs. No effect of Scintimun® or
99mTc-HMPAO-labelled
WBCs on vital signs was detected except in three patients in
whombloodpressuredecreasedafterinjectionofScintimun®.
Two of these cases of hypotension were assessed as possibly
or probably related to Scintimun®.
Blood samples for HAMAwere collected at screening and
twice after injection of Scintimun® (at 1 month and at
3 months). Four patients presented with HAMA levels above
40 μg/l at screening and were not allowed to enter the study
(screening failures). Seven patients had no HAMA assess-
ment during follow-up. Consequently, 116 patients had at
least one HAMA assessment after administration of
Scintimun®.Only16of116patients(13.8%)becamepositive
with HAMA levels >40 μg/l after Scintimun® administration.
Discussion
The results of this phase III trial show that Scintimun®
imaging is accurate, efficacious and safe in diagnosing
infection of the peripheral skeleton and provides compara-
ble information to
99mTc-HMPAO-labelled WBCs. In this
study, Scintimun® was more sensitive than
99mTc-HMPAO-
labelled WBCs in patients with microbiologically proven
infection of the bone and in patients with chronic
osteomyelitis.
The basis of the Scintimun® mechanism of action is its
nanomolar affinity to the NCA-95 (CEACAM8, CD66b)
antigen, which is found on granulocytes and mature bone
marrow cells of the granulocytic lineage [10, 11]. These
cells are present in major amounts in inflammatory and
infectious lesions and are also found in the haematopoietic
bone marrow. The typical uptake pattern of Scintimun® in
humans, therefore, includes focal uptake at sites of infection
or inflammation as well as a staining of the haematopoietic
bone marrow.
Since its introduction into clinical practice in a limited
number of European countries almost 20 years ago, the
specific accumulation of Scintimun® at sites of infection or
inflammation has been studied in various clinical indica-
tions. The majority of these studies have been conducted in
patients with osteomyelitis. Other indications include
endocarditis [12, 13], inflammatory bowel disease [14–
17], lung infection [18], the detection of perioperative
septic foci [19] and fever of unknown origin [20–22].
The most important clinical indication for Scintimun®
imaging is osteomyelitis [23]. In this context, osteomyelitic
lesions of the peripheral skeleton and of the central skeleton
have to be considered separately. In the peripheral skeleton,
osteomyelitic foci are characterized by an increased uptake
of Scintimun®. In the central skeleton the typical finding of
osteomyelitis is a focally decreased uptake (cold spot)
which is based on the displacement of normal bone marrow
by the inflammatory process. The finding of a cold spot in
the haematopoietic bone marrow of the central skeleton is
not specific for osteomyelitis but can also be caused by
other processes (e.g. metastases, haemangioma). Inherently,
therefore, a reduced specificity of Scintimun® has to be
Image quality Scintimun®
99mTc-HMPAO-labelled WBCs
Excellent 40 (11%) 13 (4%)
Good 227 (64%) 186 (52%)
Moderate 71 (20%) 110 (31%)
Poor 13 (4%) 41 (11%)
Not evaluable 6 (2%) 7 (2%)
Total no. of assessments 357 (100%)
a 357 (100%)
Table 5 Image quality as
assessed by the three readers
aTotal number of assessments is
357: 119 patients assessed by 3
readers
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reported for
99mTc-HMPAO-labelled WBCs. This consider-
ation is confirmed by data from Guhlmann et al. who
studied 36 patients with suspected chronic osteomyelitis of
the peripheral skeleton and 15 patients with suspected
chronic osteomyelitis of the central skeleton by combined
Scintimun® and conventional bone scintigraphy [24].
Sensitivity was comparable in the central and peripheral
skeleton (85 vs 91%, respectively), while specificity was
lower in the central skeleton (60 central vs 85% peripheral).
In peripheral osteomyelitis, the results of published
studies show that Scintimun® has high sensitivity and
specificity. Typically, reported values of sensitivity and
specificity in osteomyelitis range between 70 and 90% [18,
24–28]. Reuland et al. [28] studied Scintimun® in 106
patients with suspected peripheral bone infection after
surgery. The final diagnosis was obtained by microbiolog-
ical culture and clinical follow-up information. Sensitivity
was highest in the lower leg (100%), followed by thigh
(85%), knee (70%) and hip (69%). Specificity ranged
between 83 (knee) and 100% (lower leg). The high
sensitivity of Scintimun® has been confirmed by Peltier et
al. [18] in a small series of eight patients with suspected
peripheral osteomyelitis who underwent bone biopsy for
final confirmation of disease. All eight patients with
osteomyelitis were correctly identified (sensitivity 100%).
Only very limited data are available about an intra-
individual comparison of Scintimun® against alternative
scintigraphic procedures for imaging of WBCs. This
comparison is required to ultimately assess the diagnostic
value of Scintimun® against competing methods. This
study was primarily designed to provide data about the
comparison of Scintimun® with the accepted gold standard
for imaging of infection (
99mTc-HMPAO-labelled WBCs).
The results of this trial show that Scintimun® and
99mTc-
HMPAO-labelled WBCs provide comparable clinical infor-
mation in osteomyelitis. This is the first larger series of
patients studied intraindividually with both methods and
allows for the first time a direct comparison between
Scintimun® and
99mTc-HMPAO-labelled WBCs.
It is important to mention again that it was not the
primary aim of this study to evaluate sensitivity and
specificity of the two radiopharmaceuticals. Nevertheless,
sensitivity and specificity were calculated for comparative
reasons. For the calculation of sensitivity and specificity, a
truth panel decision was used as a surrogate for the true
gold standard (bone biopsy showing granulocytic accumu-
lation). The resulting values of sensitivity and specificity
were slightly lower for both radiopharmaceuticals in this
trial than the respective values in the published literature.
The reason for the lower values is most probably explained
by the very strict and controlled environment of the blinded
image evaluation that was used in this trial. All blinded
readers were completely unaware of any clinical informa-
tion related to the patients. The lack of complementary
information represents an artificial situation with limited
clinical relevance. It is assumed that imaging with
Scintimun® and
99mTc-HMPAO-labelled WBCs in a clin-
ical environment will have a greater contribution to medical
decision-making than implied by the sensitivity and
specificity values obtained in this trial. This assumption is
in line with results from an earlier phase III trial in 775
patients where Scintimun® was rated by the investigator to
supply additional information which was not provided by
other diagnostic methods in 31.5% of patients, to assure or
confirm a diagnosis already suspected by other diagnostic
methods in another 35.7% of patients, and positively
influenced the treatment strategy in 35% of patients [29].
Besides providing overall evidence for the good agreement
between Scintimun® and
99mTc-HMPAO-labelled WBCs, this
study also points towards specific differences between the
two tracers. A subanalysis of patients with acute and chronic
osteomyelitis shows that Scintimun® detects chronic osteo-
myelitis with higher sensitivity than
99mTc-HMPAO-labelled
WBCs. The high sensitivity of Scintimun® in this trial in
chronic osteomyelitis is in line with comparable values from
the literature. Kaim et al. [25] studied 24 patients with
chronic post-traumatic osteomyelitis and reported a sensitivity
of 84% and a specificity of 72% of combined Scintimun®
imaging and conventional bone scintigraphy. Slightly lower
values were published by Boubaker et al. [30] for patients
with subacute or chronic infection of hip prosthesis. Their
study involved 57 patients and yielded a sensitivity of 67%
and a specificity of 75% using microbiological examinations
and clinical follow-up as the reference.
The higher sensitivity of Scintimun® compared to
99mTc-HMPAO-labelled WBCs in chronic osteomyelitis
can be explained by two factors: the first factor is related
to the higher image quality of Scintimun® which allows
discrete increases of tracer uptake to be detected more
easily. Chronic osteomyelitis is frequently characterized by
a lower disease activity and a lower level of granulocytic
accumulation than acute osteomyelitis. A slightly increased
uptake in chronic lesions is probably detected more easily
in high-quality images. The second factor is related to the
presumed uptake mechanism of Scintimun® in osteomye-
litic lesions. Uptake of Scintimun® is supposed to involve
two components which occur in parallel: (1) targeting of
NCA-95 on circulating granulocytes in the bloodstream
with subsequent migration of Scintimun®-labelled granulo-
cytes to the inflammatory lesion and (2) transport of free
Scintimun® with the bloodstream to sites of infection with
subsequent sequestration to the extravascular space due to
an increased capillary permeability, followed by specific
binding to granulocytes which are present in the extravas-
cular space. The latter mechanism is suggested to be more
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WBCs, in contrast to Scintimun®, accumulate in osteo-
myelitic lesions only on the basis of the first mechanism
(migration of labelled cells into the lesion). It is
conceivable that the second mechanism (sequestration
of the free Scintimun® antibody to sites of infection or
inflammation with subsequent binding to granulocytes)
contributes to a relevant degree to the accumulation of
Scintimun® in chronic lesions. This difference in uptake
mechanism may also explain the higher sensitivity of
Scintimun® in patients with microbiologically confirmed
osteomyelitis.
For clinical purposes, the differentiation between infection
and sterile inflammation is of particular relevance for therapy
decisions. In clinical practice, an increase in uptake or size
over time is typically interpreted as infection, whereas a
decrease in uptake or size is assumed to represent sterile
inflammation or bone marrow activity. In this study, Scinti-
mun® and
99mTc-HMPAO-labelled WBCs could be com-
pared with regard to their ability to differentiate infection
from sterile inflammation in a subgroup of 65 patients. In
these patients, the local investigator was able to obtain a final
diagnosis on the basis of follow-up information. In these 65
patients, Scintimun® and
99mTc-HMPAO-labelled WBCs
were equally effective in differentiating between infection
and sterile inflammation.
Finally, this study provides the first systematic data
about the development of HAMA after injection of
Scintimun®. Of 116 patients, 16 developed HAMA after
Scintimun® injection and may have a potential risk of
hypersensitivity at re-exposure. According to the SmPC
2 of
Scintimun®, determination of HAMA levels is requested
before injection of Scintimun® and re-administration to
HAMA-positive patients is contraindicated.
With the exception of two cases of mild and transient
hypotension, no other parameters related to patient safety
(laboratory data, vital signs) provided evidence of an
elevated risk associated with the use of Scintimun® This
is in line with the available safety profile which is based
on some 100,000 injections and does not identify specific
safety risks.
Besides Scintimun® and labelled WBCs, other nuclear
medicine methods have also been used for the diagnosis of
osteomyelitis. The murine Fab’ fragment sulesomab targets
NCA-90 (CEACAM6, CD66c) on granulocytes and has
shown to be of value in osteomyelitis. However, affinity to
granulocytes is lower than the respective values of Scinti-
mun® [31]. Recently,
18F-fluorodeoxyglucose (FDG) in
conjunction with positron emission tomography (PET) has
been used for infection or inflammation imaging. Available
results are promising; however, the increased uptake of
18F-
FDG is due to an increased glucose metabolism and in this
regard unspecific for infection or inflammation.
In summary, Scintimun® is a promising, efficacious and
safe tool for diagnosis of osteomyelitis in the peripheral
skeleton.
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